AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical products with at least 35 batches annually, supporting stable global supply amid rising demand for resilient supply chains. The facility, opening in 2027, features advanced single-use bioreactors and aims to meet regulatory approvals across major markets including the US, Europe, and Japan. This deal highlights Japan's growing role as a strategic hub for biopharma manufacturing and AGC's global production network strength.
The U.S. SEC has approved a new Bitcoin ETF that targets three times the daily returns of Bitcoin futures, allowing investors to gain amplified exposure to Bitcoin's price movements. This leveraged product, listed on Cboe BZX and sponsored by Volatil...
The altcoin market remains bullish with a strong rally in Q3 and the Altcoin Season Index recovering, signaling potential for further gains. However, Ethereum faces challenges as its price struggles to break resistance and ETF outflows indicate weak ...
The WisdomTree Floating Rate Treasury Fund (USFR) offers investors exposure to U.S. Treasury floating-rate notes, which reset their interest rates weekly based on short-term Treasury bill rates. This structure allows USFR to benefit from rising inter...
XRP is trading near $1.50 after gaining about 16% this week, consolidating within a triangle pattern that suggests a significant price move may be imminent. Whale holdings of XRP have remained stable, indicating no major shifts from large investors. ...
XRP is nearing a key technical point where it needs to close above $1.53 on a four-hour chart to confirm a breakout. The token briefly hit $1.55 but failed to sustain above $1.53, leaving the breakout unconfirmed. If confirmed, the next target is $1....
